<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cam45755" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="pmc-domain-id">1974</journal-id><journal-id journal-id-type="pmc-domain">canmed</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10225217</article-id><article-id pub-id-type="pmcid-ver">PMC10225217.1</article-id><article-id pub-id-type="pmcaid">10225217</article-id><article-id pub-id-type="pmcaiid">10225217</article-id><article-id pub-id-type="pmid">36916310</article-id><article-id pub-id-type="doi">10.1002/cam4.5755</article-id><article-id pub-id-type="publisher-id">CAM45755</article-id><article-id pub-id-type="other">CAM4-2022-01-0101.R2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>RESEARCH ARTICLES</subject><subj-group subj-group-type="heading"><subject>Cancer Prevention</subject></subj-group></subj-group></article-categories><title-group><article-title>Racial disparities in opioid prescription and pain management among breast cancer survivors</article-title><alt-title alt-title-type="left-running-head">Kim et al.</alt-title></title-group><contrib-group><contrib id="cam45755-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Kim</surname><given-names initials="SJ">Sunny Jung</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6405-162X</contrib-id><xref rid="cam45755-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam45755-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>sun.jung.kim@vcuhealth.org</email></address></contrib><contrib id="cam45755-cr-0002" contrib-type="author"><name name-style="western"><surname>Retnam</surname><given-names initials="RP">Reuben P.</given-names></name><xref rid="cam45755-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam45755-cr-0003" contrib-type="author"><name name-style="western"><surname>Sutton</surname><given-names initials="AL">Arnethea L.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4398-0278</contrib-id><xref rid="cam45755-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam45755-cr-0004" contrib-type="author"><name name-style="western"><surname>Edmonds</surname><given-names initials="MC">Megan C.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0928-3858</contrib-id><xref rid="cam45755-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cam45755-cr-0005" contrib-type="author"><name name-style="western"><surname>Bandyopadhyay</surname><given-names initials="D">Dipankar</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5421-1725</contrib-id><xref rid="cam45755-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cam45755-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cam45755-cr-0006" contrib-type="author"><name name-style="western"><surname>Sheppard</surname><given-names initials="VB">Vanessa B.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2874-6659</contrib-id><xref rid="cam45755-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam45755-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cam45755-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Health Behavior and Policy, School of Medicine</named-content>
<institution>Virginia Commonwealth University</institution>
<city>Richmond</city>
<named-content content-type="country-part">Virginia</named-content>
<country country="US">USA</country>
</aff><aff id="cam45755-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Massey Cancer Center</named-content>
<institution>Virginia Commonwealth University</institution>
<city>Richmond</city>
<named-content content-type="country-part">Virginia</named-content>
<country country="US">USA</country>
</aff><aff id="cam45755-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Takeda Pharmaceuticals</institution>
<city>Virginia</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="cam45755-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Division of General Internal Medicine</named-content>
<institution>Icahn School of Medicine at Mount Sinai</institution>
<named-content content-type="country-part">New York</named-content>
<city>New York</city>
<country country="US">USA</country>
</aff><aff id="cam45755-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics, School of Medicine</named-content>
<institution>Virginia Commonwealth University</institution>
<city>Richmond</city>
<named-content content-type="country-part">Virginia</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Sunny Jung Kim, Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, 830 East Main Street, 4th Floor, Richmond, VA 23298, USA.<break/>
Email: <email>sun.jung.kim@vcuhealth.org</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2023</year></pub-date><volume>12</volume><issue seq="590">9</issue><issue-id pub-id-type="pmc-issue-id">436832</issue-id><issue-id pub-id-type="doi">10.1002/cam4.v12.9</issue-id><fpage>10851</fpage><lpage>10864</lpage><history><date date-type="rev-recd"><day>24</day><month>1</month><year>2023</year></date><date date-type="received"><day>30</day><month>1</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-21 16:25:26.393"><day>21</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAM4-12-10851.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAM4-12-10851.pdf"/><abstract><title>Abstract</title><sec id="cam45755-sec-0001"><title>Background</title><p>We examined whether there are racial disparities in pain management, opioid medicine prescriptions, symptom severity, and quality of life constructs in breast cancer survivors.</p></sec><sec id="cam45755-sec-0002"><title>Methods</title><p>We conducted a secondary analysis of longitudinal data from the Women's Hormonal Therapy Initiation and Persistence (WHIP) study (<italic toggle="no">n</italic>&#160;=&#160;595), a longitudinal study of hormonal receptor&#8208;positive breast cancer survivors. Upon study enrollment, patients completed a survey assessing an array of psychological, behavioral, and treatment outcomes, including adjuvant endocrine therapy (AET)&#8208;induced symptoms, and provided a saliva biospecimen. Opioid prescription records were extracted from the health maintenance organizations (HMOs) pharmacy database. The final analytic sample included women with complete HMO pharmacy records for 1&#8201;year.</p></sec><sec id="cam45755-sec-0003"><title>Results</title><p>There were 251 eligible patients, of which 169 (67.3%) were White. The average age was 61.09&#8201;years old (<italic toggle="no">SD</italic>&#160;=&#160;11.07). One hundred seventy&#8208;two patients (68.5%) had received at least one opioid medication and 37.1% were prescribed opioids longer than 90&#8201;days (<italic toggle="no">n</italic>&#160;=&#160;93). Sixty&#8208;four Black patients (78%) had a record of being prescribed with opioids compared to 64% of White patients (<italic toggle="no">n</italic>&#160;=&#160;108, <italic toggle="no">p</italic>&#160;=&#160;0.03). Black patients reported worse vasomotor, neuropsychological, and gastrointestinal symptoms, as well as lower quality of life and greater healthcare discrimination than White patients (<italic toggle="no">p's</italic>&#8201;&lt;&#8201;0.05). Black patients were more likely to be prescribed opioids for 90 days or longer compared to White patients, when controlling for age, marital status, income, body mass index (BMI), cancer stage, and chemotherapy status (adjusted Odds Ratio = 2.72, <italic toggle="yes">p</italic> = 0.014).</p></sec><sec id="cam45755-sec-0004"><title>Conclusion</title><p>Findings indicate that there are racial differences in opioid prescriptions supplied for pain management and symptomatic outcomes. Future research is needed to understand the causes of disparities in cancer pain management and symptomatic outcomes.</p></sec></abstract><abstract abstract-type="graphical"><p>We found racial disparities in opioid prescriptions and symptomatic outcomes among cancer patients. Black cancer patients were more likely to be prescribed opioids compared to White patients. Black patients reported worse vasomotor, neuropsychological, and gastrointestinal symptoms, as well as lower quality of life than White patients.<boxed-text position="anchor" content-type="graphic" id="cam45755-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAM4-12-10851-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam45755-kwd-0001">cancer patients</kwd><kwd id="cam45755-kwd-0002">opioids</kwd><kwd id="cam45755-kwd-0003">pain management disparity</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Cancer Institute
</institution><institution-id institution-id-type="doi">10.13039/100000054</institution-id></institution-wrap></funding-source><award-id>P30 CA016059</award-id><award-id>R01CA154848</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Center for Advancing Translational Sciences
</institution><institution-id institution-id-type="doi">10.13039/100006108</institution-id></institution-wrap></funding-source><award-id>UL1TR002649</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="14"/><word-count count="7199"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.8 mode:remove_FC converted:28.05.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="CAM45755-cit-2001"><string-name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Retnam</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Sutton</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Edmonds</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Bandyopadhyay</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>VB</given-names></string-name>. <article-title>Racial disparities in opioid prescription and pain management among breast cancer survivors</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>:<fpage>10851</fpage>&#8208;<lpage>10864</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.5755</pub-id><pub-id pub-id-type="pmid">36916310</pub-id><pub-id pub-id-type="pmcid">PMC10225217</pub-id></mixed-citation>
</p></notes></front><body id="cam45755-body-0001"><sec id="cam45755-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Cancer survivors experience post&#8208;treatment complications and morbidities. Pain is one of the prevalent health problems in cancer survivors resulting from the tumor, exposure to treatment, or other medical comorbidities. Chronic pain is as prevalent as 40% among cancer survivor populations,<xref rid="cam45755-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> with the most common form of chronic pain being neuropathic pain.<xref rid="cam45755-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Chronic pain in cancer survivors can last for months to years, which can significantly reduce quality of life.<xref rid="cam45755-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cam45755-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> While nonpharmacologic therapies alone may be used to treat mild cancer&#8208;related pain, pharmacologic treatment that involves opioids is often used as part of therapy for cancer&#8208;related pain.<xref rid="cam45755-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cam45755-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>According to the National Cancer Institute, a cancer survivor is an individual who remains alive during and after overcoming cancer; thus, cancer survivorship starts from the time of diagnosis and lasts until the end of life.<xref rid="cam45755-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Cancer survivors have a high rate of opioid use.<xref rid="cam45755-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Younger age, unemployment at the time of cancer diagnosis, increased comorbidity, and prior alcohol use were associated with increased adjusted odds of opioid use.<xref rid="cam45755-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> There are growing concerns about the risks of long&#8208;term opioid use and racial disparities in pain management among cancer survivors.<xref rid="cam45755-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> It is reported that cancer patients of racial and ethnic minorities showed greater comorbidities and encounter more barriers to receiving quality of care than other patient groups.<xref rid="cam45755-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Black and Hispanic cancer survivors are more likely to experience barriers to receiving pain treatment and limited access to healthcare due to inability to afford the cost of medications even with insurance coverage.<xref rid="cam45755-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> A recent systematic review indicates that cancer patients of racial and ethnic minorities receive less optimal care for acute and chronic pain than do Whites even after controlling for age, sex, and pain severity.<xref rid="cam45755-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cam45755-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Cancer survivors with racial and ethnic minorities consistently underreported pain intensity, which, in part, contributed to unmet needs of pain management.<xref rid="cam45755-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cam45755-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="cam45755-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Cancer survivors of racial and ethnic minorities were also more likely than Whites to report low quality of life caused by untreated pain.<xref rid="cam45755-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Understanding the associations between opioid treatment exposure and health conditions between racial groups is critical from a health equity standpoint to improve the quality of care of individuals of racial minorities.<xref rid="cam45755-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cam45755-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>The severity of chronic pain is relatively higher in certain cancer subpopulations, such as breast cancer survivors.<xref rid="cam45755-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cam45755-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Breast cancer survivors prescribed with adjuvant endocrine therapy (AET) are at an elevated risk for pain, comorbidities, and adverse effects (e.g., vasomotor symptoms).<xref rid="cam45755-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Quality of life and symptomatic outcomes are shown to vary by pain severity and pain management.<xref rid="cam45755-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Although opioid therapy is widely used to treat moderate to severe cancer&#8208;related pain, given the reported patterns of racial disparities in cancer&#8208;related health outcomes, it is critical to examine whether AET breast cancer survivors of racial and ethnic minorities are more likely to experience adverse effects of opioid use than their White counterparts, and how those adverse effects are related to the duration of opioids prescribed.<xref rid="cam45755-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Despite the accumulating evidence of racial disparities in pain management and differing treatment outcomes by chronic opioid use, there is a dearth of research directly investigating how various symptomatic outcomes and quality of life among AET breast cancer survivors differ by race and exposure to opioids prescribed. To understand treatment outcomes and characteristics of cancer survivors who are prescribed opioid medicines for a long period of time, we examined a wide range of symptomatic outcomes, quality of life, and psychological parameters across racial groups as well as opioid prescription status (e.g., nonopioid prescribed, chronic opioids prescribed). We hypothesized that Black AET breast cancer survivors are more likely to report worse symptomatic outcomes, low quality of life, and greater pain than Whites, and that these health conditions are worse among those who were prescribed opioids for a long term versus those with non&#8208; or short&#8208;term exposure to opioid medicines.</p></sec><sec sec-type="methods" id="cam45755-sec-0006"><label>2</label><title>METHODS</title><sec id="cam45755-sec-0007"><label>2.1</label><title>Data collection</title><p>The study is a secondary data analysis from the Women's Hormonal Therapy Initiation and Persistence (WHIP) study, a longitudinal study that sought to understand endocrine therapy adherence and patient outcomes in breast cancer survivors.<xref rid="cam45755-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="cam45755-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> In this study, women with hormone receptor&#8208;positive (HR+) breast cancer were recruited from integrated health systems, communities, and organizations in Washington D.C.; Atlanta, GA; and Detroit, MI. The study eligibility criteria included self&#8208;identified as either African American or White, &#8805;21&#8201;years of age, diagnosed with HR+ (estrogen&#8208;receptor&#8208;positive [ER+] and/or progesterone&#8208;receptor&#8208;positive [PR+]) breast cancer within 1&#160;year of study enrollment, between stage 0 and III breast cancer, and prescribed adjuvant endocrine therapy (AET), and having filled a prescription script based on pharmacy records for any type of AET (e.g., tamoxifen) within 1&#8208;year postdiagnosis. Medical and pharmacy records were provided by each institution to capture the type of AET that patients were prescribed and confirm that women had current AET prescription at the time of survey.</p><p>Among the 2318 women recruited in the WHIP study, 600 were eligible and consented through telephone surveys administered by trained clinical research assistants. Pharmacy fill and refill data for opioid prescriptions dispensed within 1&#8208;year psotdiagnosis over the study period were reviewed and extracted for the final study sample. Women with complete pharmacy records for 1&#8208;year postdiagnosis were included in the present study. The final sample of this secondary data analysis consists of 251 women. Screening, recruitment, and data extraction procedures adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<xref rid="cam45755-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The screening process is reported in Figure&#160;<xref rid="cam45755-fig-0001" ref-type="fig">1</xref>. The WHIP study was approved by the Institutional Review Boards at participating institutes. Study protocols adhered to the standards of the Health Insurance Portability and Accountability Act. Detailed methods and recruitment procedures pertaining to the present WHIP study can be found elsewhere.<xref rid="cam45755-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="cam45755-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="cam45755-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Recruitment and data collection process.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CAM4-12-10851-g002.jpg"/></fig></sec><sec id="cam45755-sec-0008"><label>2.2</label><title>Measures</title><p>At baseline, patients completed a self&#8208;reported survey assessing demographics, cancer treatment history, evaluations on healthcare delivery, psychosocial measures, and symptom severity. We also obtained informed consent to extract saliva biospecimen data and medical and pharmacy records.</p><sec id="cam45755-sec-0009"><label>2.2.1</label><title>Opioid prescription records</title><p>The types of opioids and duration of prescriptions were extracted from health records of breast cancer survivors (<italic toggle="yes">n</italic>&#160;=&#160;251). We adapted the morphine milligram equivalent conversion calculator (MME) to classify the types of opioid medications supplied per patient.<xref rid="cam45755-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="cam45755-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The types of opioid medicines included mild, medium, or severe opioid medications. Based on the MME conversion values, severe opioids included oxycodone, methadone, or fentanyl; moderate opioids included morphine, hydromorphone, or hydrocodone; and mild opioids included use of codeine or tramadol. In our analysis, we classified opioid prescription status by the duration of opioid prescriptions supplied. A long&#8208;term opioid prescription was defined as 90&#8201;days of consecutive opioid prescription supplied after diagnosis.</p></sec><sec id="cam45755-sec-0010"><label>2.2.2</label><title>Demographics and cancer treatment status</title><p>At baseline, we measured age, race/ethnicity, marital status, height/weight, income, employment status, and education. Information on cancer stage (defined by the American Joint Committee on Cancer [AJCC] staging system)<xref rid="cam45755-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> as well as treatment types (chemotherapy [yes/no], radiation therapy [yes/no], hormone therapy [yes/no]) were extracted from medical records.</p></sec><sec id="cam45755-sec-0011"><label>2.2.3</label><title>Patient satisfaction on healthcare delivery</title><p>A prevalidated Patient Satisfaction Questionnaire Short&#8208;form (PSQ&#8208;18) was administered on a five&#8208;point Likert scale to assess general satisfaction toward cancer care (e.g., &#8220;The medical care I have been receiving is just about perfect&#8221;), technical quality (e.g., &#8220;I think my doctor's office has everything needed to provide complete medical care&#8221;), interpersonal manner (e.g., &#8220;My doctors treat me in a very friendly and courteous manner&#8221;), communication (e.g., &#8220;Doctors are good about explaining the reasons for medical tests&#8221;), financial security/confidence (e.g., &#8220;I feel confident that I can get the medical care I need without being set back financially&#8221;), time spent (e.g., &#8220;Doctors usually spend plenty of time with me&#8221;), and access convenience (e.g., &#8220;I have easy access to the medical specialists I need&#8221;).<xref rid="cam45755-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Prior to computing composite scores for each subscale, several items were reverse&#8208;coded to indicate that higher scores mean greater satisfaction toward cancer care and treatment, greater technical quality, better interpersonal manner, better communication, better financial security/confidence, less waiting time and more time with doctors, better time efficiency, and easier access.</p></sec><sec id="cam45755-sec-0012"><label>2.2.4</label><title>Beliefs about medicine questionnaire (<styled-content style="fixed-case" toggle="no">BMQ</styled-content>)</title><p>The BMQ consists of two subscales: &#8216;perceived necessity of medication&#8217; and &#8216;perceived concerns of taking the medication&#8217;.<xref rid="cam45755-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The perceived necessity subscale includes five items, such as &#8220;my current health depends on my hormonal therapy medications&#8221; and &#8220;without my hormonal therapy medications, I would become very ill.&#8221; Additionally, the perceived concern subscale includes five items on a five&#8208;point <italic toggle="yes">Likert</italic> scale (e.g., &#8220;my hormonal therapy medications will protect me from becoming worse,&#8221; &#8220;I sometimes worry about the long&#8208;term effects of my hormonal therapy medications&#8221;). Higher scores indicate greater perceived necessity and concerns.</p></sec><sec id="cam45755-sec-0013"><label>2.2.5</label><title>Medical outcomes study (<styled-content style="fixed-case" toggle="no">MOS</styled-content>) social support survey</title><p>An eight&#8208;item emotional support questionnaire (e.g., &#8220;Someone to confide in or talk to about yourself or your problems&#8221;) and a four&#8208;item tangible support questionnaire (e.g., &#8220;someone to prepare your meals if you were unable to do it yourself&#8221;) were administered on a five&#8208;point <italic toggle="yes">Likert</italic> scale. A higher score indicates having better emotional support and tangible support.<xref rid="cam45755-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec><sec id="cam45755-sec-0014"><label>2.2.6</label><title>Functional assessment of cancer <styled-content style="fixed-case" toggle="no">therapy&#8208;breast</styled-content> [<styled-content style="fixed-case" toggle="no">FACT&#8208;B</styled-content>]</title><p>The prevalidated 37&#8208;item FACT&#8208;B instrument was implemented to measure multidimensional quality of life in patients with breast cancer, including the subscales for Physical Well&#8208;Being (PWB), Emotional Well&#8208;Being (EWB), Social/Family Well&#8208;Being (SWB), and Functional Well&#8208;Being (FWB), as well as 10 additional items of the Breast Cancer Subscale (BCS). The FACT&#8208;B total score was computed in accordance with the FACT&#8208;B scoring guidelines.<xref rid="cam45755-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="cam45755-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="cam45755-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Higher scores indicate greater overall well&#8208;being and less health&#8208;related concerns.</p></sec><sec id="cam45755-sec-0015"><label>2.2.7</label><title>Functional assessment of cancer therapy&#8212;endocrine symptoms (<styled-content style="fixed-case" toggle="no">FACT&#8208;ES</styled-content>)</title><p>A total of 23 items were administered to assess self&#8208;reported concerns related to symptoms participants experienced in the past 7&#8201;days. Of those 23 items, 19 were adopted from the prevalidated FACT&#8208;ES version 4 Additional Concern section. We also added three items to measure gastrointestinal symptoms (i.e., &#8220;I have experienced weight loss,&#8221;. &#8220;I have an increased appetite,&#8221; and &#8220;I have high cholesterol&#8221;) and one item to assess other concerns (i.e., &#8220;I have experienced bone loss&#8221;). Severity of endocrine symptoms and concerns regarding vasomotor (e.g., &#8220;I have night sweats,&#8221; &#8220;&#8230;hot flashes,&#8221; &#8220;&#8230;cold sweats&#8221;), neuropsychological (e.g., dizziness), gastrointestinal (e.g., &#8220;I have experienced weight loss&#8221;), gynecological and other symptoms (e.g., joint pain, stiffness) were measured on a five&#8208;point <italic toggle="yes">Likert</italic> scale.<xref rid="cam45755-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Higher scores indicate worse symptoms (0&#160;=&#160;not at all, 4&#160;=&#160;very much).</p></sec><sec id="cam45755-sec-0016"><label>2.2.8</label><title>Psychological distress</title><p>At baseline, the level of distress was measured by the National Comprehensive Cancer Network's (NCCN) Distress Thermometer (DT) item on a 11&#8208;point <italic toggle="yes">Likert</italic> scale. The DT item asked participants to &#8220;<italic toggle="yes">indicate on a scale of 0 to 10, how you would best describe how much distress you have been experiencing in the past week including today. Zero represents no distress and ten represents extreme distress</italic>.&#8221; Following the NCCN distress management guidelines, responses were categorized into three levels. Scores from 0 to 4 were coded as &#8220;1= Distress levels are well under control&#8221; scores from 5 to 6 were categorized to &#8220;2= Experience some distress&#8221;; and values 7 or higher were coded as &#8220;3= Experience high levels of distress.&#8221;<xref rid="cam45755-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p></sec><sec id="cam45755-sec-0017"><label>2.2.9</label><title>Social psychological factors</title><p>At baseline, patients were asked about religiosity with a nice&#8208;item scale on a four&#8208;point <italic toggle="yes">Likert</italic> scale (e.g., &#8220;I talk openly about my faith with others&#8221;)<xref rid="cam45755-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>; medical mistrust with seven items on a five&#8208;point <italic toggle="yes">Likert</italic> scale (e.g., &#8220;Patients have sometimes been deceived or mislead by health care organizations&#8221;)<xref rid="cam45755-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="cam45755-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>; perceived discrimination in the medical system,<xref rid="cam45755-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> using the prevalidated 14 items, where responses were on a binary scale (yes&#160;=&#160;1, no&#160;=&#160;0, e.g., &#8220;&#8230;been treated with less respect than other people because of your race&#8221;); and 12 items on a four&#8208;point <italic toggle="yes">Likert</italic> scale assessing self&#8208;efficacy in understanding healthcare and obtaining health information. Summated values were computed for religiosity, mistrust, perceived discrimination, and self&#8208;efficacy. Higher scores indicate more religiosity, greater medical mistrust, greater discrimination perceived, and higher self&#8208;efficacy.</p></sec></sec><sec id="cam45755-sec-0018"><label>2.3</label><title>Data analysis</title><p>To examine pain management outcomes stratified by race, we compared an array of factors and self&#8208;reported outcomes between Black (<italic toggle="yes">n</italic>&#160;=&#160;82) and White participants (<italic toggle="yes">n</italic>&#160;=&#160;169). Next, to examine factors related to opioid prescription versus nonopioid prescription, patients who have not been prescribed opioids were categorized as &#8216;no opioid prescription&#8217; (<italic toggle="yes">n</italic>&#160;=&#160;79). The rest of the patients were categorized as patients with opioid prescription (<italic toggle="yes">n</italic>&#160;=&#160;172). Lastly, we compared factors and outcomes related to long&#8208;term opioid prescription. Ninety&#8208;three patients fell under the long&#8208;term (chronic) opioid prescription category (i.e., 90&#8201;days of consecutive opioid prescription after diagnosis). We conducted unequal&#8208;variances t&#8208;tests for continuous constructs and chi&#8208;squared tests for categorical variables. We then performed a logistic regression model on opioid prescription status while controlling for covariates (age, income, BMI, marital status, cancer stage, and treatment received). Controlling for the covariates, we also conducted a logistic regression on chronic opioid prescription status. Surgery type was not added to the chronic opioid use model due to possible convergence failure that can be caused by the small number of cases within categories.<xref rid="cam45755-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> As shown in Table&#160;<xref rid="cam45755-tbl-0001" ref-type="table">1</xref>, two of the categories reported 5 cases and 6 cases: each of these was less than 3% of the sample.</p><table-wrap position="float" id="cam45755-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographics and characteristics of study participants according to race (<italic toggle="no">N</italic>&#160;=&#160;251).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Overall</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Total (<italic toggle="yes">N</italic>&#160;=&#160;251)</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Stratified by race</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Test statistics</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Black (<italic toggle="yes">n</italic>&#160;=&#160;82)</th><th align="left" valign="bottom" rowspan="1" colspan="1">White (<italic toggle="yes">n</italic>&#160;=&#160;169)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">61.09 (11.07)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>58.84 (10.69)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>62.18 (11.11)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#8722;2.29</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital Status&#160;=&#160;Married (%)</td><td align="left" valign="top" rowspan="1" colspan="1">149 (59.4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>36 (43.9)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>113 (66.9)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>11.13**</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Income &#8805;100&#8201;k (%)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (25.2)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>8 (10.7)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>51 (32.1)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>11.28**</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education &#8804;High school (%)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (23.2)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (17.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Employment (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Part&#8208;time</td><td align="left" valign="top" rowspan="1" colspan="1">36 (14.6)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (14.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Full&#8208;time</td><td align="left" valign="top" rowspan="1" colspan="1">85 (34.4)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (38.3)</td><td align="left" valign="top" rowspan="1" colspan="1">54 (32.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">126 (51.0)</td><td align="left" valign="top" rowspan="1" colspan="1">38 (46.9)</td><td align="left" valign="top" rowspan="1" colspan="1">88 (53.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">29.75 (6.95)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>32.87 (7.37)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>28.27 (6.24)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>4.54**</bold>
</underline>
</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Cancer stage (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">151 (64.3)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>39 (51.3)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>112 (70.4)</bold>
</td><td rowspan="3" align="left" valign="top" colspan="1">
<bold>8.33*</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">69 (29.4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>31 (40.8)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>38 (23.9)</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">15 (6.4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>6 (7.9)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>9 (5.7)</bold>
</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Surgery type (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No surgery</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lumpectomy</td><td align="left" valign="top" rowspan="1" colspan="1">129 (58.1)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (49.3)</td><td align="left" valign="top" rowspan="1" colspan="1">94 (62.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mastectomy</td><td align="left" valign="top" rowspan="1" colspan="1">82 (36.9)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (40.8)</td><td align="left" valign="top" rowspan="1" colspan="1">53 (35.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Both</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (5.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiation&#160;=&#160;Radiation (%)</td><td align="left" valign="top" rowspan="1" colspan="1">142 (74.0)</td><td align="left" valign="top" rowspan="1" colspan="1">49 (81.7)</td><td align="left" valign="top" rowspan="1" colspan="1">93 (70.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemotherapy, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">89 (35.6)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>40 (49.4)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>49 (29.0)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>9.06**</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic Opioid Prescription, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">93 (37.1)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>39 (47.6)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>54 (32.0)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.12</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication Tamoxifen, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">75 (30.1)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (36.2)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (27.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adherence, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.30)</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.21)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Activity, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">1403.65 (1771.62)</td><td align="left" valign="top" rowspan="1" colspan="1">1101.42 (1853.34)</td><td align="left" valign="top" rowspan="1" colspan="1">1547.66 (1719.02)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sitting, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">58.63 (30.58)</td><td align="left" valign="top" rowspan="1" colspan="1">63.52 (36.13)</td><td align="left" valign="top" rowspan="1" colspan="1">56.34 (27.44)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Patient satisfaction questionnaire (PAQ&#8208;18)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">General satisfaction, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">15.68 (3.10)</td><td align="left" valign="top" rowspan="1" colspan="1">15.42 (3.21)</td><td align="left" valign="top" rowspan="1" colspan="1">15.80 (3.06)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Technical quality, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">12.10 (2.14)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>11.58 (2.17)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>12.35 (2.09)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#8722;2.49*</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Interpersonal manner, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">8.55 (1.28)</td><td align="left" valign="top" rowspan="1" colspan="1">8.53 (1.21)</td><td align="left" valign="top" rowspan="1" colspan="1">8.56 (1.31)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Communication, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">8.12 (1.43)</td><td align="left" valign="top" rowspan="1" colspan="1">8.06 (1.36)</td><td align="left" valign="top" rowspan="1" colspan="1">8.15 (1.47)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Financial aspect, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">7.45 (2.01)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>6.74 (2.23)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>7.79 (1.80)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>&#8722;3.52**</bold>
</underline>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Time spent, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">7.82 (1.41)</td><td align="left" valign="top" rowspan="1" colspan="1">7.62 (1.49)</td><td align="left" valign="top" rowspan="1" colspan="1">7.91 (1.36)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Access convenience, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">12.43 (1.85)</td><td align="left" valign="top" rowspan="1" colspan="1">12.25 (1.93)</td><td align="left" valign="top" rowspan="1" colspan="1">12.52 (1.81)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMQ medication necessity, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">13.83 (3.08)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>14.41 (2.86)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>13.55 (3.16)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.09*</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMQ medication concerns, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">11.28 (2.98)</td><td align="left" valign="top" rowspan="1" colspan="1">11.69 (3.40)</td><td align="left" valign="top" rowspan="1" colspan="1">11.07 (2.73)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MOS emotional support, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">82.12 (19.81)</td><td align="left" valign="top" rowspan="1" colspan="1">81.74 (19.35)</td><td align="left" valign="top" rowspan="1" colspan="1">82.30 (20.08)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MOS tangible support, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">80.23 (23.83)</td><td align="left" valign="top" rowspan="1" colspan="1">79.83 (24.02)</td><td align="left" valign="top" rowspan="1" colspan="1">80.43 (23.81)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FACT&#8208;B score, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">115.26 (17.32)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>109.14 (18.26)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>118.18 (16.11)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>&#8722;3.59**</bold>
</underline>
</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">FACT&#8208;endocrine subscale</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Vasomotor symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">4.05 (3.64)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>4.80 (3.60)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.70 (3.62)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.13*</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neuropsychological symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">3.33 (3.20)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>4.20 (3.25)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>2.93 (3.10)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>2.74**</bold>
</underline>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">3.71 (3.49)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>4.53 (3.84)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.33 (3.26)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.27*</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gynecologic symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">4.63 (3.92)</td><td align="left" valign="top" rowspan="1" colspan="1">4.95 (3.65)</td><td align="left" valign="top" rowspan="1" colspan="1">4.48 (4.04)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">2.49 (1.93)</td><td align="left" valign="top" rowspan="1" colspan="1">2.57 (1.77)</td><td align="left" valign="top" rowspan="1" colspan="1">2.45 (2.03)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Distress (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Under control</td><td align="left" valign="top" rowspan="1" colspan="1">153 (61.7)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (58.8)</td><td align="left" valign="top" rowspan="1" colspan="1">106 (63.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Some distress</td><td align="left" valign="top" rowspan="1" colspan="1">61 (24.6)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (25.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High distress</td><td align="left" valign="top" rowspan="1" colspan="1">34 (13.7)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (17.5)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (11.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Religiosity, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">28.80 (6.67)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>32.59 (4.14)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>26.96 (6.90)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>8.03**</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mistrust, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">20.65 (4.70)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>23.02 (4.73)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>19.51 (4.25)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>5.64**</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Perceived discrimination, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">14.83 (2.41)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>16.12 (3.82)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>14.20 (0.67)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>4.24**</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Self&#8208;efficacy, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">44.54 (3.66)</td><td align="left" valign="top" rowspan="1" colspan="1">44.27 (3.57)</td><td align="left" valign="top" rowspan="1" colspan="1">44.68 (3.71)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cam45755-ntgp-0001"><fn id="cam45755-note-0001"><p>
<italic toggle="yes">Note</italic>: Values in bold <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. Values in bold and underlined <italic toggle="yes">p</italic>&#160;&#8804;&#8201;0.01. Only significant statistical coefficients are reported.</p></fn><fn id="cam45755-note-0002"><p>Abbreviations: BMQ, beliefs about medicine questionnaire; MOS, medical outcomes study.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="results" id="cam45755-sec-0019"><label>3</label><title>RESULTS</title><p>Among the screened (<italic toggle="yes">n</italic>&#160;=&#160;2318), 600 patients were eligible and provided consent. Among 595 participants who completed the baseline survey, 344 were excluded due to incomplete health record data (see Figure&#160;<xref rid="cam45755-fig-0001" ref-type="fig">1</xref> for detail), leading to the final sample of 251 patients. Most of our sample was White (<italic toggle="yes">n</italic>&#160;=&#160;169, 67.3%) and married (<italic toggle="yes">n</italic>&#160;=&#160;149, 59.4%), and the average age was 61.09&#8201;years old (<italic toggle="yes">SD</italic>&#160;=&#160;11.07). Approximately 20% of the participants (<italic toggle="yes">n</italic>&#160;=&#160;48) received a high school education or less, and 34.4% of the patients (<italic toggle="yes">n</italic>&#160;=&#160;85) reported having full&#8208;time employment (Table&#160;<xref rid="cam45755-tbl-0001" ref-type="table">1</xref> for participant characteristics).</p><sec id="cam45755-sec-0020"><label>3.1</label><title>Opioid prescriptions</title><p>One hundred seventy&#8208;two patients (68.5%) were prescribed opioids at least once, and 93 patients in the sample (37.1%) were on prescribed opioid medicines for 90 consecutive days or longer after diagnosis. Ninety&#8208;seven patients (38.6%) were prescribed with severe opioids (i.e., oxycodone, methadone, fentanyl), and 63 were prescribed with these severe opioid medicines for 90&#8201;days or longer. More than one fourth of the patients in our sample were prescribed moderate opioids (i.e., morphine, hydromorphone, hydrocodone; <italic toggle="yes">n</italic>&#160;=&#160;122, 48.6%), and 75 received long&#8208;term moderate opioid medicines. Forty&#8208;two patients (16.7%) were prescribed with mild opioids (i.e., codeine, tramadol), and 34 patients were on mild opioids for 90&#8201;days or longer. The average opioid prescription score was 2.50 (<italic toggle="yes">SD&#160;=</italic>&#160;2.21). Black patients (<italic toggle="yes">n</italic>&#160;=&#160;39, 47.6%) were more likely than White patients (<italic toggle="yes">n</italic>&#160;=&#160;54, 32%) to be prescribed with opioid medicines for a long term (i.e., using 90 consecutive days after diagnosis), <italic toggle="yes">Chi&#8208;sq</italic>&#160;=&#160;5.12, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 (Table&#160;<xref rid="cam45755-tbl-0001" ref-type="table">1</xref>).</p></sec><sec id="cam45755-sec-0021"><label>3.2</label><title>Racial disparities in <styled-content style="fixed-case" toggle="no">self&#8208;reported</styled-content> outcomes</title><p>Black patients reported lower financial security and confidence in receiving medical care than Whites (<italic toggle="yes">t</italic>&#160;=&#160;&#8722;3.52, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.1). Black patients (<italic toggle="yes">M</italic>&#160;=&#160;118.18, <italic toggle="yes">SD</italic>&#160;=&#160;16.11) were more likely than Whites (<italic toggle="yes">M</italic>&#160;=&#160;109.14, <italic toggle="yes">SD</italic>&#160;=&#160;18.26) to experience lower quality of life and more health&#8208;related concerns as shown in FACT&#8208;B scores (<italic toggle="yes">t</italic>&#160;=&#160;&#8722;3.59, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Additionally, Black patients were more likely than Whites to experience worse vasomotor (<italic toggle="yes">t</italic>&#160;=&#160;2.13, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), gastrointestinal (<italic toggle="yes">t</italic>&#160;=&#160;2.27, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) and neuropsychological symptoms (<italic toggle="yes">t</italic>&#160;=&#160;2.74, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). With regards to psychosocial outcomes, Black patients reported stronger religious belief (<italic toggle="yes">t</italic>&#160;=&#160;8.03, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), greater mistrust toward medical healthcare organizations (<italic toggle="yes">t</italic>&#160;=&#160;5.64, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), and greater perceived discrimination (<italic toggle="yes">t</italic>&#160;=&#160;4.24, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) than White patients (Table&#160;<xref rid="cam45755-tbl-0001" ref-type="table">1</xref>).</p></sec><sec id="cam45755-sec-0022"><label>3.3</label><title>Differences in <styled-content style="fixed-case" toggle="no">self&#8208;reported</styled-content> outcomes by opioid prescription status</title><sec id="cam45755-sec-0023"><label>3.3.1</label><title>Healthcare delivery</title><p>Patients who had mastectomy only or both mastectomy and lumpectomy were more likely to be prescribed opioid medicines for a long term than patients who received lumpectomy only (<italic toggle="yes">Chi&#8208;sq</italic>&#160;=&#160;16.90, <italic toggle="yes">p&#160;=&#160;0</italic>.008). Nearly 50% of the patients prescribed with opioid medicines for 90&#8201;days or longer had received chemotherapy, whereas only 28.7% of the patients with no&#8208; or short&#8208;term opioid medicines had chemotherapy (<italic toggle="yes">Chi&#8208;sq&#8201;=</italic>&#160;8.07, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, Table&#160;<xref rid="cam45755-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="cam45755-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Descriptive statistics stratified by opioid use status.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th rowspan="3" align="left" valign="top" colspan="1"/><th align="left" colspan="3" valign="top" rowspan="1">Opioid prescription supplied</th><th align="left" colspan="3" valign="top" rowspan="1">Chronic opioid prescription</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">No opioid prescribed</th><th align="left" valign="top" rowspan="1" colspan="1">Opioid prescribed</th><th align="left" valign="top" rowspan="1" colspan="1">t&#8208;test</th><th align="left" valign="top" rowspan="1" colspan="1">False</th><th align="left" valign="top" rowspan="1" colspan="1">True</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8208;test</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;79</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;172</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;158</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;93</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Race&#160;=&#160;White (%)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>61 (77.2)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>108 (62.8)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>4.49</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>115 (72.8)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>54 (58.1)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.12</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>64.09 (10.86)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>59.72 (10.92)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>2.96</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>63.01 (10.61)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>57.83 (11.12)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>3.63</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status, married (%)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>39 (49.4)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>110 (64.0)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">90 (57.0)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (63.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Income, &#8805;100&#8201;k (%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (23.3)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (26.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">37 (25.7)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (24.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education, &lt;high school (%)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (17.9)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (19.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">32 (20.5)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (17.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Employment (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Part&#8208;time</td><td align="left" valign="top" rowspan="1" colspan="1">9 (11.4)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">23 (14.7)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Full&#8208;time</td><td align="left" valign="top" rowspan="1" colspan="1">23 (29.1)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (36.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">48 (30.8)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (40.7)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">47 (59.5)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (47.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">85 (54.5)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (45.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">29.12 (7.29)</td><td align="left" valign="top" rowspan="1" colspan="1">30.08 (6.77)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">29.45 (7.41)</td><td align="left" valign="top" rowspan="1" colspan="1">30.31 (6.04)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Cancer stage (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">41 (55.4)</td><td align="left" valign="top" rowspan="1" colspan="1">110 (68.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">97 (65.1)</td><td align="left" valign="top" rowspan="1" colspan="1">54 (62.8)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">27 (36.5)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (26.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">43 (28.9)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (30.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">6 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (5.6)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">9 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (7.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Surgery type (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No surgery</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>2 (1.5)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>3 (3.4)</bold>
</underline>
</td><td rowspan="4" align="left" valign="top" colspan="1">
<underline underline-style="single">
<bold>16.90</bold>
</underline>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lumpectomy</td><td align="left" valign="top" rowspan="1" colspan="1">40 (63.5)</td><td align="left" valign="top" rowspan="1" colspan="1">89 (56.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>93 (68.9)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>36 (41.4)</bold>
</underline>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mastectomy</td><td align="left" valign="top" rowspan="1" colspan="1">21 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (38.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>38 (28.1)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>44 (50.6)</bold>
</underline>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Both</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>2 (1.5)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>4 (4.6)</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiation&#160;=&#160;radiation (%)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (70.7)</td><td align="left" valign="top" rowspan="1" colspan="1">101 (75.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">93 (78.2)</td><td align="left" valign="top" rowspan="1" colspan="1">49 (67.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemotherapy&#160;=&#160;chemotherapy (%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (31.6)</td><td align="left" valign="top" rowspan="1" colspan="1">64 (37.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>45 (28.7)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>44 (47.3)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>8.07</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication tamoxifen, n(%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (25.6)</td><td align="left" valign="top" rowspan="1" colspan="1">55 (32.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">46 (29.3)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (31.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adherence, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.97 (0.16)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.92 (0.27)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.04</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.21)</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.30)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Activity, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">1479.11 (1880.43)</td><td align="left" valign="top" rowspan="1" colspan="1">1364.62 (1718.06)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1345.01 (1609.41)</td><td align="left" valign="top" rowspan="1" colspan="1">1512.54 (2046.00)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sitting, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">57.22 (30.38)</td><td align="left" valign="top" rowspan="1" colspan="1">59.35 (30.76)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">58.19 (29.99)</td><td align="left" valign="top" rowspan="1" colspan="1">59.47 (31.85)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">PAQ&#8208;18</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">General satisfaction, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">15.89 (2.94)</td><td align="left" valign="top" rowspan="1" colspan="1">15.56 (3.19)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>16.08 (2.80)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>14.92 (3.50)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>2.53</bold>
</underline>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Technical quality, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">12.17 (1.96)</td><td align="left" valign="top" rowspan="1" colspan="1">12.06 (2.23)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">12.32 (1.94)</td><td align="left" valign="top" rowspan="1" colspan="1">11.69 (2.42)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Interpersonal manner, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">8.53 (1.33)</td><td align="left" valign="top" rowspan="1" colspan="1">8.56 (1.26)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">8.61 (1.26)</td><td align="left" valign="top" rowspan="1" colspan="1">8.45 (1.32)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Communication, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">8.22 (1.38)</td><td align="left" valign="top" rowspan="1" colspan="1">8.06 (1.46)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">8.12 (1.41)</td><td align="left" valign="top" rowspan="1" colspan="1">8.10 (1.48)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Financial aspect, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">7.53 (1.80)</td><td align="left" valign="top" rowspan="1" colspan="1">7.41 (2.11)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7.63 (1.90)</td><td align="left" valign="top" rowspan="1" colspan="1">7.13 (2.17)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Time spent, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">7.61 (1.52)</td><td align="left" valign="top" rowspan="1" colspan="1">7.93 (1.34)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7.83 (1.44)</td><td align="left" valign="top" rowspan="1" colspan="1">7.79 (1.36)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Access convenience, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">12.42 (1.71)</td><td align="left" valign="top" rowspan="1" colspan="1">12.44 (1.93)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">12.52 (1.78)</td><td align="left" valign="top" rowspan="1" colspan="1">12.27 (1.98)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMQ medication necessity, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">14.33 (3.15)</td><td align="left" valign="top" rowspan="1" colspan="1">13.62 (3.04)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">13.93 (3.04)</td><td align="left" valign="top" rowspan="1" colspan="1">13.68 (3.16)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMQ medication concerns, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">11.31 (2.96)</td><td align="left" valign="top" rowspan="1" colspan="1">11.26 (2.99)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">11.03 (2.83)</td><td align="left" valign="top" rowspan="1" colspan="1">11.69 (3.18)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MOS emotional support, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">79.48 (20.27)</td><td align="left" valign="top" rowspan="1" colspan="1">83.34 (19.53)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">81.27 (21.39)</td><td align="left" valign="top" rowspan="1" colspan="1">83.57 (16.75)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MOS tangible support, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">76.28 (24.68)</td><td align="left" valign="top" rowspan="1" colspan="1">82.07 (23.27)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">78.19 (24.78)</td><td align="left" valign="top" rowspan="1" colspan="1">83.72 (21.81)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FACT&#8208;B score, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">116.24 (17.30)</td><td align="left" valign="top" rowspan="1" colspan="1">114.76 (17.37)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>117.20 (16.65)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>111.65 (18.06)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.25</bold>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Endocrine subscale (ES)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Vasomotor symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">4.33 (3.98)</td><td align="left" valign="top" rowspan="1" colspan="1">3.90 (3.46)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">3.97 (3.70)</td><td align="left" valign="top" rowspan="1" colspan="1">4.19 (3.55)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neuropsychological symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">3.50 (3.37)</td><td align="left" valign="top" rowspan="1" colspan="1">3.24 (3.11)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.97 (2.95)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>4.01 (3.55)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#8722;2.18</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">4.18 (3.89)</td><td align="left" valign="top" rowspan="1" colspan="1">3.47 (3.26)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">3.63 (3.49)</td><td align="left" valign="top" rowspan="1" colspan="1">3.86 (3.51)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gynecologic symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">4.66 (4.62)</td><td align="left" valign="top" rowspan="1" colspan="1">4.61 (3.52)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">4.56 (4.12)</td><td align="left" valign="top" rowspan="1" colspan="1">4.76 (3.55)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other symptoms, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">2.50 (2.02)</td><td align="left" valign="top" rowspan="1" colspan="1">2.49 (1.89)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2.39 (1.96)</td><td align="left" valign="top" rowspan="1" colspan="1">2.71 (1.88)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Distress (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>6.08</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Under control</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>53 (67.1)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>100 (59.2)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">101 (64.3)</td><td align="left" valign="top" rowspan="1" colspan="1">52 (57.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Some distress</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>12 (15.2)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>49 (29.0)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">34 (21.7)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (29.7)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High distress</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>14 (17.7)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>20 (11.8)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">22 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (13.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Religiosity, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">28.33 (6.04)</td><td align="left" valign="top" rowspan="1" colspan="1">29.02 (6.95)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">28.75 (6.37)</td><td align="left" valign="top" rowspan="1" colspan="1">28.88 (7.20)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mistrust, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">20.03 (4.47)</td><td align="left" valign="top" rowspan="1" colspan="1">20.93 (4.79)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>20.00 (4.24)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>21.73 (5.24)</bold>
</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">
<bold>&#8722;2.69</bold>
</underline>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Perceived discrimination, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">14.57 (2.28)</td><td align="left" valign="top" rowspan="1" colspan="1">14.96 (2.48)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">14.60 (2.10)</td><td align="left" valign="top" rowspan="1" colspan="1">15.24 (2.87)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Self&#8208;efficacy, <italic toggle="yes">M</italic> (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">44.40 (3.79)</td><td align="left" valign="top" rowspan="1" colspan="1">44.61 (3.62)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">44.47 (3.75)</td><td align="left" valign="top" rowspan="1" colspan="1">44.66 (3.53)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cam45755-ntgp-0002"><fn id="cam45755-note-0004"><p>Nonopioid users are those who have not been prescribed to opioid (no); opioid users are those who have been prescribed to opioid (yes); Values in bold with different superscripts indicate significant difference between two groups at a <italic toggle="yes">p</italic>&#8208;value less than 0.05. Chronic opioid prescription is defined as 90&#8201;days of consecutive opioid supply after diagnosis.</p></fn><fn id="cam45755-note-0003"><p>
<italic toggle="yes">Note</italic>: Values in bold <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. Values in bold and underlined <italic toggle="yes">p</italic>&#160;&#8804;&#8201;0.01.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cam45755-sec-0024"><label>3.3.2</label><title>
<styled-content style="fixed-case" toggle="no">AET</styled-content> symptom severity and psychosocial factors</title><p>We found that neuropsychological symptoms were significantly worse among patients prescribed with opioid medicines for 90&#8201;days or longer (<italic toggle="yes">M</italic>&#160;=&#160;4.01, <italic toggle="yes">SD</italic>&#160;=&#160;3.55) than those without opioid medicine prescribed (<italic toggle="yes">M</italic>&#160;=&#160;2.97, <italic toggle="yes">SD</italic>&#160;=&#160;2.95, <italic toggle="yes">t</italic>&#160;=&#160;&#8722;2.18, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Patients prescribed with opioid medicines for a long&#8208;term reported significantly lower satisfaction toward the care (<italic toggle="yes">t</italic>&#160;=&#160;2.53, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), worse well&#8208;being and more health&#8208;related concerns (<italic toggle="yes">t</italic>&#160;=&#160;2.25, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), and greater mistrust (<italic toggle="yes">t</italic>&#160;=&#160;&#8722;2.69, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) than those without prescribed opioid medicines (see Table&#160;<xref rid="cam45755-tbl-0002" ref-type="table">2</xref> for details).</p></sec><sec id="cam45755-sec-0025"><label>3.3.3</label><title>Racial disparities in opioid prescription status and long&#8208;term opioid prescriptions</title><p>Logistic regression models confirmed that racial disparity in opioid prescription status and long&#8208;term opioid prescription remained. More specifically, the odds of opioid prescriptions in Black patients were 3.38 times that of opioid prescription occurring in White patients (CI: 1.46&#8211;8.36, <italic toggle="yes">p</italic>&#160;=&#160;0.006) even after controlling for age, marital status, income, BMI, cancer stage, and chemotherapy status. The odds of chronic opioid prescription in Black patients were 2.72 times the odds of chronic opioid prescription happening in White patients (CI: 1.23&#8211;6.16, <italic toggle="yes">p</italic>&#160;=&#160;0.014) after controlling for the same list of covariates (i.e., age, marital status, income, BMI, cancer stage, and chemotherapy status, Table&#160;<xref rid="cam45755-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="cam45755-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Logistic regression models.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Predictors</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratios</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="4" valign="top" rowspan="1">Opioid prescription</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Race [Black vs. White]</td><td align="left" valign="top" rowspan="1" colspan="1">3.38</td><td align="left" valign="top" rowspan="1" colspan="1">1.46&#8211;8.36</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.006</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.92&#8211;0.99</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.020</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Marital status [Married vs. Other]</td><td align="left" valign="top" rowspan="1" colspan="1">2.87</td><td align="left" valign="top" rowspan="1" colspan="1">1.42&#8211;5.97</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Income [&#8805;100&#8201;k vs. &lt;100&#8201;k]</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.43&#8211;2.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.996</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.94&#8211;1.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.783</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Stage [II vs. I]</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.16&#8211;0.82</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.016</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Stage [III vs. I]</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.09&#8211;1.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.164</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Chemotherapy [chemotherapy vs. no chemotherapy]</td><td align="left" valign="top" rowspan="1" colspan="1">1.23</td><td align="left" valign="top" rowspan="1" colspan="1">0.56&#8211;2.75</td><td align="left" valign="top" rowspan="1" colspan="1">0.614</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adherence</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.06&#8211;1.88</td><td align="left" valign="top" rowspan="1" colspan="1">0.320</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Distress [some distress vs. no distress]</td><td align="left" valign="top" rowspan="1" colspan="1">2.52</td><td align="left" valign="top" rowspan="1" colspan="1">1.12&#8211;6.03</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.030</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Distress [high distress vs. no distress]</td><td align="left" valign="top" rowspan="1" colspan="1">1.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.40&#8211;2.71</td><td align="left" valign="top" rowspan="1" colspan="1">0.969</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Chronic opioid prescription</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Race [Black vs. White]</td><td align="left" valign="top" rowspan="1" colspan="1">2.72</td><td align="left" valign="top" rowspan="1" colspan="1">1.23&#8211;6.16</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.014</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">0.95</td><td align="left" valign="top" rowspan="1" colspan="1">0.91&#8211;0.98</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Marital status [Married vs. Other]</td><td align="left" valign="top" rowspan="1" colspan="1">1.66</td><td align="left" valign="top" rowspan="1" colspan="1">0.81&#8211;3.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.175</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Income [&#8805;100&#8201;k vs. &lt;100&#8201;k]</td><td align="left" valign="top" rowspan="1" colspan="1">1.26</td><td align="left" valign="top" rowspan="1" colspan="1">0.56&#8211;2.81</td><td align="left" valign="top" rowspan="1" colspan="1">0.577</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.94&#8211;1.04</td><td align="left" valign="top" rowspan="1" colspan="1">0.677</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Stage [II vs. I]</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.22&#8211;1.12</td><td align="left" valign="top" rowspan="1" colspan="1">0.101</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Stage [III vs. I]</td><td align="left" valign="top" rowspan="1" colspan="1">0.73</td><td align="left" valign="top" rowspan="1" colspan="1">0.16&#8211;3.13</td><td align="left" valign="top" rowspan="1" colspan="1">0.677</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Chemotherapy [Chemotherapy vs. No Chemotherapy]</td><td align="left" valign="top" rowspan="1" colspan="1">1.85</td><td align="left" valign="top" rowspan="1" colspan="1">0.87&#8211;3.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.111</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">General satisfaction</td><td align="left" valign="top" rowspan="1" colspan="1">0.91</td><td align="left" valign="top" rowspan="1" colspan="1">0.81&#8211;1.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.104</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">FACT&#8208;B score</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.96&#8211;1.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.381</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neuropsychological symptoms</td><td align="left" valign="top" rowspan="1" colspan="1">1.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.90&#8211;1.16</td><td align="left" valign="top" rowspan="1" colspan="1">0.713</td></tr></tbody></table><table-wrap-foot id="cam45755-ntgp-0003"><fn id="cam45755-note-0005"><p>
<italic toggle="yes">Note</italic>: In these models, we controlled for age, marital status, income, BMI, cancer stage, and chemotherapy status. Values in bold are significant <italic toggle="yes">p</italic>&#8208;values.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec sec-type="discussion" id="cam45755-sec-0026"><label>4</label><title>DISCUSSION</title><p>Opioid prescribing rates in cancer survivors are relatively high even after attaining 10 or more years of cancer survivorship.<xref rid="cam45755-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Opioids can be effective in treating acute and severe pain, but adverse effects among breast cancer survivors that commonly occur with opioid use are alarming.<xref rid="cam45755-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Moreover, our secondary data analysis indicates possible overprescribing of opioids among Black breast cancer patients. We analyzed health record and survey data of breast cancer patients who received adjuvant endocrine therapy (i.e., aromatase inhibitors vs. Tamoxifen) and identified demographic, healthcare delivery, symptomatic, and psychological characteristics associated with exposure to opioid treatments (e.g., chronic vs. nonchronic prescriptions) and race (Black vs. White). More than two&#8208;third of patients had at least one prescription of opioids within the past 12&#8201;months, and 54% of them were prescribed opioid medicines for 90 consecutive days or longer after diagnosis. We found that overall breast cancer patients who were prescribed opioid medicines for a long term were more likely to report dissatisfaction, mistrust, and poor neuropsychological outcomes compared to those who were not exposed to opioid medicines. Some prior work reported associations between chronic opioid use and adverse effects, such as mental fogginess, central sleep apnea, and opioid&#8208;induced hyperalgesia in noncancer patients.<xref rid="cam45755-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="cam45755-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Yet, empirical evidence for benefits and risks of long&#8208;term opioid treatments in breast cancer patients is largely limited. To best of our knowledge, our findings specific to breast cancer patients reporting associations between chronic opioid prescription and neuropsychological outcomes as well as attitudes toward healthcare system are novel, thus contributing to the literature.</p><p>We examined racial disparities in pain management between Black and White breast cancer survivors. Our regression models suggest that the odds of short&#8208;term opioid prescription as well as chronic opioid prescriptions were significantly higher among Black patients compared to White patients, even after controlling for covariates. In the current literature, findings on whether Black cancer patients tend to receive higher doses and more potent opioid prescriptions compared to other races are mixed. On the one hand, a study reported the opposite of what we found in our analysis.<xref rid="cam45755-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Using the Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI) nationwide database containing 106,732 military veteran cancer survivors diagnosed between 2000 and 2015, Vitzthum and colleagues found that white race was associated with the risk of increased adjusted odds of persistent opioid prescriptions received after the onset of curative treatment.<xref rid="cam45755-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> In this dataset, other factors associated with persistent opioid prescriptions include younger age, unemployment at the time of cancer diagnosis, lower income, increased comorbidity, and current or prior tobacco use. On the other hand, Meghani et al.<xref rid="cam45755-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> found that African American patients with cancer pain were more likely than White counterparts to receive morphine with toxic metabolites (i.e., morphine 3&#8208; and 6&#8208;glucuronide), which are known to be neurotoxic and attribute to chronic kidney disease.<xref rid="cam45755-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Meghani et al. also reported that African American patients with cancer were more likely to be prescribed morphine&#8208;based medications but less likely to be prescribed oxycodone&#8208;based medications than White patients with cancer.</p><p>These mixed findings can be due to variation in characteristics of the selected samples, research settings where data were obtained, or variables that influence the direction and magnitude of the association between race and the level of opioid prescriptions. Conducting a meta&#8208;analysis of findings related to racial disparities in opioid prescriptions received as well as understanding mechanisms of disproportionate opioid&#8208;related treatments and adverse effects by race will help further elucidate disparities in cancer pain treatment and survivorship outcomes.</p><p>We also found that Black patients were more likely to report worse symptomatic and psychological outcomes compared to White counterparts: Black patients reported worse neuropsychological, vasomotor, and gastrointestinal symptoms, as well as lower FACT&#8208;B scores (indicative of poor physical, social, emotional, and functional well&#8208;being) and greater perceived discrimination and mistrust than White patients. In our study, the vasomotor symptom disparity mean ratio between Black and White participants was 29.7, and the neuropsychological symptom disparity mean ratio was 43.3. In the current literature, however, there is limited evidence reporting racial differences in vasomotor and neuropsychological symptoms among breast cancer survivors. One study reported that there was no difference in vasomotor symptoms between Hispanic and non&#8208;Hispanic breast cancer survivors.<xref rid="cam45755-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> According to O'Keefe and colleagues, in 2010 the breast cancer mortality disparity ratio between Black and White women with breast cancers was 41.8.<xref rid="cam45755-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Given this nationwide mortality disparity ratio, the disparity found in our study could be clinically meaningful.</p><p>Our findings suggest that racial disparities exist in symptomatic and psychological outcomes, requiring closer examination of the reasons for these disparities. The gap in vasomotor and neuropsychological symptoms between Black and White patients could be a contributing factor to the differences in gastrointestinal symptoms. Or, the worse neuropsychological, vasomotor, and gastrointestinal symptoms reported in Black patients could be due to environmental factors, such as limited access to high quality pain care and longer delay to treatment.<xref rid="cam45755-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Reasons for these disparities should be examined further in future studies.</p><p>Findings from our logistic regression models also raise concerns about the potential consequences of chronic opioid prescriptions that were more pronounced in Black cancer survivors than their White counterparts. Our findings imply unmet needs of pain management among Black cancer survivors who may have had limited resources for alternative treatments for pain management other than opioids. Given that exposure to chronic opioid prescriptions was associated with deficits in a wide range of symptomatic outcomes, cancer patients of racial minorities might be at an elevated risk to negative outcomes associated with chronic opioid therapy. These findings are consistent with the current literature on cancer pain management reporting that patients receiving persistent opioids medicines are at a greater risk for comorbidities and negative health outcomes.<xref rid="cam45755-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="cam45755-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Tan and colleagues found that breast cancer patients with pain who used opioids were significantly associated with nonadherence to vital adjuvant endocrine therapies and at greater risk for mortality after adjusting for adherence.<xref rid="cam45755-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Furthermore, as shown in our study, exposure to chronic opioid treatment was significantly associated with lower quality of life, psychological comorbidities, and greater concerns about health.</p><p>Other nonsignificant and mixed results noteworthy and counterinitiative include: the proportion of Black patients taking Tamoxifen (36.2%) was greater than that of White patients (27.2%) although statistically not significant (Table&#160;<xref rid="cam45755-tbl-0001" ref-type="table">1</xref>); and higher cancer stage was not always associated with chronic opioid exposure (Table&#160;<xref rid="cam45755-tbl-0003" ref-type="table">3</xref>). Given that tamoxifen is known to cause arthralgias,<xref rid="cam45755-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> and patients with progressed cancer stage often need opioid medicines for cancer&#8208;related pain, future research should further examine these associations.</p><p>Other than these pharmacologic approaches in treating cancer survivors, it will be beneficial to develop social and behavioral medicines for supportive care of cancer survivors, such as Petrocchi et al.'s smartphone&#8208;based intervention to engage and empower breast cancer patients<xref rid="cam45755-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> and Alavi et al.'s web&#8208;based psychotherapy for mental health of cancer survivors.<xref rid="cam45755-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Social and behavioral medicines are concerned with patients' psychological, behavioral, and social needs and refer to integrating social and behavioral science knowledge and practices into treatment and prevention of illness to enhance the overall quality of patient care and life.<xref rid="cam45755-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Future research should focus on integrating principles of social and behavioral medicines to develop easily accessible interventions such as the aforementioned technology&#8208;based behavioral therapies in treating pain and improving the overall quality of life of cancer survivors.</p><sec id="cam45755-sec-0027"><label>4.1</label><title>Limitations</title><p>Our study must be interpreted with limitations imposed by the study design and research setting. First, to be eligible participants had to be diagnosed with HR+ breast cancer within 1&#160;year of survey enrollment. The extracted opioid prescription data included a history of opioids prescribed for up to 1&#8208;year postdiagnosis. Within the up to 1&#8208;year postdiagnosis period, we identified whether a participant was prescribed opioids (yes vs. no) and for how long (over 90&#8201;days or less). When a patient was prescribed opioids and how long after opioid prescriptions each patient took the survey varied by patients. Overall, the mean difference between first opioid prescription date and survey completion date was 288&#8201;days. However, it is possible some participants took the survey while actively taking opioid medications, whereas others were no longer taking opioid medicines when participating in the survey. Thus, self&#8208;reported outcomes (e.g., symptoms) cannot be always interpreted as an immediate outcome of the exposure to opioids prescribed, and we did not make causality claims out of the findings, but associations. Future study should conduct a longitudinal follow&#8208;up study with exact timestamp data between these activities to fully understand the consequences of chronic opioid exposure among breast cancer survivors.</p><p>Second, it should be noted that during the screening process, over half the sample was excluded due to incomplete HMO pharmacy records. Given our study objectives, individual&#8208;level HMO data were necessary; thus, those without such data were considered ineligible. However, this exclusion could have invited potential biases in the results. To rule out any threat to sampling bias, future research should track if there is any demographic difference between the excluded sample and included sample.</p><p>Third, though one of the strengths of the study is the inclusion of data from multiple data sources (i.e., self&#8208;reported patient surveys and health records), the sample size is relatively small for subgroup analysis after screening out ineligible patients. Future work may include a large enough sample size for diverse subgroup analyses by geosocial determinant factors, such as rurality versus urbanicity that previously demonstrated significant disparities in opioid overdose problems and treatment outcomes.<xref rid="cam45755-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="cam45755-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="cam45755-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="cam45755-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> However, within our sample (<italic toggle="yes">n</italic>&#160;=&#160;251), we still found significant differences across racial groups and several clinically important findings. Our analysis confirmed that breast cancer patients receiving chemotherapy were more likely to be on chronic opioid treatment than those who did not receive chemotherapy. Yet, the current dataset only reports a binary response of whether chemotherapy was given (yes or no). To further understand the granularity of chronic opioid use among cancer patients who underwent chemotherapy, it will be critical to assess the types and duration of chemotherapeutics given. Future research is required to address and validate this clinically important association by using a comprehensive dataset containing treatment variables such as the types of chemotherapeutics and AET as well as related biomedical markers.</p><p>Lastly, the study did not have a drug in&#8208;take monitoring system that tracked opioid consumption, but rather used prescribing patterns extracted from pharmacy health records. With the present dataset, it is not known whether patients truly took the opioid medications they were prescribed. With this study condition, our statistical findings related to disparities should be interpreted as exposure to opioid medicines and opioid prescriptions supplied, rather than opioid medications consumed. Given that data on opioid in&#8208;take was not available, future studies should implement a protocol that tracks opioid in&#8208;take records.</p></sec></sec><sec sec-type="conclusions" id="cam45755-sec-0028"><label>5</label><title>CONCLUSION</title><p>There were racial disparities in pain management, symptoms, and quality of life associated with exposure to chronic opioid medicines. Among breast cancer patients with AET, those supplied with opioid medicines for 90&#8201;days or longer were more likely to report dissatisfaction, mistrust toward health system, and poor neuropsychological symptoms than those who did not receive long&#8208;term opioid medicines. These differences between cancer survivors who were prescribed opioid medicines and those who were not emphasize the need for alternative nonpharmacologic approaches, such as supportive care by trained providers for managing post&#8208;treatment pain and technology&#8208;based interventions grounded in social and behavioral medicine sciences.</p></sec><sec id="cam45755-sec-0031"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Sunny Jung Kim:</bold> Conceptualization (lead); investigation (lead); methodology (lead); writing &#8211; original draft (lead); writing &#8211; review and editing (lead). <bold>Reuben P. Retnam:</bold> Formal analysis (lead); writing &#8211; review and editing (supporting). <bold>Arnethea L. Sutton:</bold> Data curation (supporting); investigation (supporting); project administration (supporting). <bold>Megan C. Edmonds:</bold> Data curation (supporting); project administration (supporting); writing &#8211; review and editing (supporting). <bold>Dipankar Bandyopadhyay:</bold> Formal analysis (supporting); supervision (supporting); writing &#8211; review and editing (supporting). <bold>Vanessa B. Sheppard:</bold> Conceptualization (supporting); funding acquisition (lead); supervision (supporting); writing &#8211; review and editing (supporting).</p></sec></body><back><sec sec-type="data-availability" id="cam45755-sec-0030"><title>DATA AVAILABILITY STATEMENT</title><p>Data available on request due to privacy/ethical restrictions: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></sec><ref-list content-type="cited-references" id="cam45755-bibl-0001"><title>REFERENCES</title><ref id="cam45755-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam45755-cit-0001"><string-name name-style="western"><surname>van den Beuken&#8208;van Everdingen</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>de Rijke</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kessels</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Schouten</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>van Kleef</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Patijn</surname><given-names>J</given-names></string-name>. <article-title>Prevalence of pain in patients with cancer: a systematic review of the past 40&#8201;years</article-title>. <source>Ann Oncol</source>. <year>2007</year>;<volume>18</volume>(<issue>9</issue>):<fpage>1437</fpage>&#8208;<lpage>1449</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdm056</pub-id><pub-id pub-id-type="pmid">17355955</pub-id></mixed-citation></ref><ref id="cam45755-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam45755-cit-0002"><string-name name-style="western"><surname>Mossey</surname><given-names>JM</given-names></string-name>. <article-title>Defining racial and ethnic disparities in pain management</article-title>. <source>Clin Orthop Relat Res</source>. <year>2011</year>;<volume>469</volume>(<issue>7</issue>):<fpage>1859</fpage>&#8208;<lpage>1870</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11999-011-1770-9</pub-id><pub-id pub-id-type="pmid">21249483</pub-id><pub-id pub-id-type="pmcid">PMC3111792</pub-id></mixed-citation></ref><ref id="cam45755-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam45755-cit-0003"><string-name name-style="western"><surname>Glare</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Finlay</surname><given-names>E</given-names></string-name>, et al. <article-title>Pain in cancer survivors</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>16</issue>):<fpage>1739</fpage>&#8208;<lpage>1747</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.52.4629</pub-id><pub-id pub-id-type="pmid">24799477</pub-id><pub-id pub-id-type="pmcid">PMC4031191</pub-id></mixed-citation></ref><ref id="cam45755-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam45755-cit-0004"><string-name name-style="western"><surname>Shah</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Raji</surname><given-names>MA</given-names></string-name>. <article-title>Long&#8208;term opioid therapy in older cancer survivors: a retrospective cohort study</article-title>. <source>J Am Geriatr Soc</source>. <year>2019</year>;<volume>67</volume>(<issue>5</issue>):<fpage>945</fpage>&#8208;<lpage>952</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgs.15945</pub-id><pub-id pub-id-type="pmid">31026356</pub-id><pub-id pub-id-type="pmcid">PMC6645777</pub-id></mixed-citation></ref><ref id="cam45755-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam45755-cit-0005"><string-name name-style="western"><surname>Sutradhar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lokku</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barbera</surname><given-names>L</given-names></string-name>. <article-title>Cancer survivorship and opioid prescribing rates: a population&#8208;based matched cohort study among individuals with and without a history of cancer</article-title>. <source>Cancer</source>. <year>2017</year>;<volume>123</volume>(<issue>21</issue>):<fpage>4286</fpage>&#8208;<lpage>4293</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.30839</pub-id><pub-id pub-id-type="pmid">28782114</pub-id></mixed-citation></ref><ref id="cam45755-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam45755-cit-0006"><string-name name-style="western"><surname>Paice</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Portenoy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lacchetti</surname><given-names>C</given-names></string-name>, et al. <article-title>Management of chronic pain in survivors of adult cancers: American society of clinical oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source>. <year>2016</year>;<volume>34</volume>(<issue>27</issue>):<fpage>3325</fpage>&#8208;<lpage>3345</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2016.68.5206</pub-id><pub-id pub-id-type="pmid">27458286</pub-id></mixed-citation></ref><ref id="cam45755-bib-0007"><label>7</label><mixed-citation publication-type="miscellaneous" id="cam45755-cit-0007"><collab collab-type="authors">National Cancer Institute</collab>
. <article-title>NCI dictionaries: &#8220;survivor&#8221;</article-title>. [Internet]. In: National Cancer Institute, editor. Bethesda, MD <year>2022</year>.</mixed-citation></ref><ref id="cam45755-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam45755-cit-0008"><string-name name-style="western"><surname>Vitzthum</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Riviere</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sheridan</surname><given-names>P</given-names></string-name>, et al. <article-title>Predicting persistent opioid use, abuse, and toxicity among cancer survivors</article-title>. <source>J Natl Cancer Inst</source>. <year>2019</year>;<volume>112</volume>(<issue>7</issue>):<fpage>720</fpage>&#8208;<lpage>727</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djz200</pub-id><pub-id pub-id-type="pmcid">PMC7357328</pub-id><pub-id pub-id-type="pmid">31754696</pub-id></mixed-citation></ref><ref id="cam45755-bib-0009"><label>9</label><mixed-citation publication-type="book" id="cam45755-cit-0009"><string-name name-style="western"><surname>Mead</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cartwright&#8208;Smith</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Woods</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Siegel</surname><given-names>B</given-names></string-name>. <source>Racial and ethnic disparities in U.S. Health Care: A Chartbook</source>. <publisher-name>The Commonwealth Fund</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="cam45755-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam45755-cit-0010"><string-name name-style="western"><surname>Stein</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Alcaraz</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Kamson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fallon</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>TG</given-names></string-name>. <article-title>Sociodemographic inequalities in barriers to cancer pain management: a report from the American Cancer Society's study of cancer survivors&#8208;II (SCS&#8208;II)</article-title>. <source>Psychooncology</source>. <year>2016</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1212</fpage>&#8208;<lpage>1221</lpage>. Epub 2016/07/17. doi:<pub-id pub-id-type="doi">10.1002/pon.4218</pub-id><pub-id pub-id-type="pmid">27421683</pub-id></mixed-citation></ref><ref id="cam45755-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam45755-cit-0011"><string-name name-style="western"><surname>Shavers</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Bakos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>VB</given-names></string-name>. <article-title>Race, ethnicity, and pain among the U.S. adult population</article-title>. <source>J Health Care Poor Underserved</source>. <year>2010</year>;<volume>21</volume>(<issue>1</issue>):<fpage>177</fpage>&#8208;<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1353/hpu.0.0255</pub-id><pub-id pub-id-type="pmid">20173263</pub-id></mixed-citation></ref><ref id="cam45755-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam45755-cit-0012"><string-name name-style="western"><surname>Hausmann</surname><given-names>LRM</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Kwoh</surname><given-names>KC</given-names></string-name>. <article-title>Racial disparities in the monitoring of patients on chronic opioid therapy</article-title>. <source>PainPain</source>. <year>2013</year>;<volume>154</volume>(<issue>1</issue>):<fpage>46</fpage>&#8208;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pain.2012.07.034</pub-id><pub-id pub-id-type="pmid">23273103</pub-id></mixed-citation></ref><ref id="cam45755-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam45755-cit-0013"><string-name name-style="western"><surname>Chen</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kurz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pasanen</surname><given-names>M</given-names></string-name>, et al. <article-title>Racial differences in opioid use for chronic nonmalignant pain</article-title>. <source>J General Int Med</source>. <year>2005</year>;<volume>20</volume>(<issue>7</issue>):<fpage>593</fpage>&#8208;<lpage>598</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1525-1497.2005.0106.x</pub-id><pub-id pub-id-type="pmcid">PMC1490156</pub-id><pub-id pub-id-type="pmid">16050852</pub-id></mixed-citation></ref><ref id="cam45755-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam45755-cit-0014"><string-name name-style="western"><surname>Green</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Hart&#8208;Johnson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Loeffler</surname><given-names>DR</given-names></string-name>. <article-title>Cancer&#8208;related chronic pain: examining quality of life in diverse cancer survivors</article-title>. <source>Cancer</source>. <year>2011</year>;<volume>117</volume>(<issue>9</issue>):<fpage>1994</fpage>&#8208;<lpage>2003</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.25761</pub-id><pub-id pub-id-type="pmid">21509777</pub-id></mixed-citation></ref><ref id="cam45755-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam45755-cit-0015"><string-name name-style="western"><surname>Peuckmann</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ekholm</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Rasmussen</surname><given-names>NK</given-names></string-name>, et al. <article-title>Chronic pain and other sequelae in long&#8208;term breast cancer survivors: Nationwide survey in Denmark</article-title>. <source>Eur J Pain</source>. <year>2009</year>;<volume>13</volume>(<issue>5</issue>):<fpage>478</fpage>&#8208;<lpage>485</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejpain.2008.05.015</pub-id><pub-id pub-id-type="pmid">18635381</pub-id></mixed-citation></ref><ref id="cam45755-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam45755-cit-0016"><string-name name-style="western"><surname>Schou Bredal</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Smeby</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Ottesen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Warncke</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schlichting</surname><given-names>E</given-names></string-name>. <article-title>Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain</article-title>. <source>J Pain Symptom Manage</source>. <year>2014</year>;<volume>48</volume>(<issue>5</issue>):<fpage>852</fpage>&#8208;<lpage>862</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpainsymman.2013.12.239</pub-id><pub-id pub-id-type="pmid">24703940</pub-id></mixed-citation></ref><ref id="cam45755-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam45755-cit-0017"><string-name name-style="western"><surname>Pinkerton</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>JR</given-names></string-name>. <article-title>Opioid addiction and misuse in adult and adolescent patients with cancer</article-title>. <source>Intern Med JInternal medicine journal</source>. <year>2017</year>;<volume>47</volume>(<issue>6</issue>):<fpage>632</fpage>&#8208;<lpage>636</lpage>. doi:<pub-id pub-id-type="doi">10.1111/imj.13449</pub-id><pub-id pub-id-type="pmid">28580748</pub-id></mixed-citation></ref><ref id="cam45755-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam45755-cit-0018"><string-name name-style="western"><surname>Sheppard</surname><given-names>VB</given-names></string-name>, <string-name name-style="western"><surname>Hurtado&#8208;de&#8208;Mendoza</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y&#8208;L</given-names></string-name>, et al. <article-title>Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine</article-title>. <source>J Cancer Surviv</source>. <year>2018</year>;<volume>12</volume>(<issue>1</issue>):<fpage>74</fpage>&#8208;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11764-017-0646-8</pub-id><pub-id pub-id-type="pmid">29147853</pub-id></mixed-citation></ref><ref id="cam45755-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam45755-cit-0019"><string-name name-style="western"><surname>Sheppard</surname><given-names>VB</given-names></string-name>, <string-name name-style="western"><surname>Sutton</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hurtado&#8208;de&#8208;Mendoza</surname><given-names>A</given-names></string-name>, et al. <article-title>Race and ptient&#8208;reported symptoms in adherence to adjuvant endocrine therapy: a report from the Women's hormonal initiation and persistence study</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2021</year>;<volume>30</volume>(<issue>4</issue>):<fpage>699</fpage>&#8208;<lpage>709</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1055-9965.Epi-20-0604</pub-id><pub-id pub-id-type="pmid">33514603</pub-id><pub-id pub-id-type="pmcid">PMC8330157</pub-id></mixed-citation></ref><ref id="cam45755-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam45755-cit-0020"><string-name name-style="western"><surname>von Elm</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Vandenbroucke</surname><given-names>JP</given-names></string-name>. <article-title>Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>BMJ (Clinical Research Ed)</source>. <year>2007</year>;<volume>335</volume>(<issue>7624</issue>):<fpage>806</fpage>&#8208;<lpage>808</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.39335.541782.AD</pub-id><pub-id pub-id-type="pmcid">PMC2034723</pub-id><pub-id pub-id-type="pmid">17947786</pub-id></mixed-citation></ref><ref id="cam45755-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="cam45755-cit-0021"><collab collab-type="authors">World Health Organization</collab>
. <article-title>WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Table A6.2, Approximate potency of opioids relative to morphine; PO and immediate&#8208;release formulations unless stated otherwisea. Geneva</article-title>. <year>2018</year>.<pub-id pub-id-type="pmid">30776210</pub-id></mixed-citation></ref><ref id="cam45755-bib-0022"><label>22</label><mixed-citation publication-type="book" id="cam45755-cit-0022"><collab collab-type="authors">Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors</collab>
. <source>Centers for Medicare &amp; Medicaid Services (CMS)</source>. <publisher-name>U.S. Dept. of Health &amp; Human Services</publisher-name>; <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/guidance/document/opioid-oral-morphine-milligram-equivalent-mme-conversion-factors-0" ext-link-type="uri">https://www.hhs.gov/guidance/document/opioid&#8208;oral&#8208;morphine&#8208;milligram&#8208;equivalent&#8208;mme&#8208;conversion&#8208;factors&#8208;0</ext-link>. Accessed September 23, 2022.</mixed-citation></ref><ref id="cam45755-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam45755-cit-0023"><string-name name-style="western"><surname>Giuliano</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Connolly</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Edge</surname><given-names>SB</given-names></string-name>, et al. <article-title>Breast cancer&#8208;major changes in the American joint committee on cancer eighth edition cancer staging manual</article-title>. <source>CA Cancer J Clin</source>. <year>2017</year>;<volume>67</volume>(<issue>4</issue>):<fpage>290</fpage>&#8208;<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21393</pub-id><pub-id pub-id-type="pmid">28294295</pub-id></mixed-citation></ref><ref id="cam45755-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="cam45755-cit-0024"><string-name name-style="western"><surname>Marshall</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Hays</surname><given-names>RD</given-names></string-name>. <article-title>The Patient Satisfaction Questionnaire Short&#8208;Form (PSQ&#8208;18)</article-title>. <year>1994</year>.</mixed-citation></ref><ref id="cam45755-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam45755-cit-0025"><string-name name-style="western"><surname>Hurtado&#8208;de&#8208;Mendoza</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Jennings</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>VB</given-names></string-name>. <article-title>Understanding breast Ccncer Ssrvivors' beliefs and concerns about adjuvant hormonal therapy: promoting adherence</article-title>. <source>J Cancer Educ</source>. <year>2018</year>;<volume>33</volume>(<issue>2</issue>):<fpage>436</fpage>&#8208;<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13187-017-1180-0</pub-id><pub-id pub-id-type="pmid">28205022</pub-id><pub-id pub-id-type="pmcid">PMC5557694</pub-id></mixed-citation></ref><ref id="cam45755-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam45755-cit-0026"><string-name name-style="western"><surname>Sherbourne</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>AL</given-names></string-name>. <article-title>The MOS social support survey</article-title>. <source>Soc Sci Med (1982)</source>. <year>1991</year>;<volume>32</volume>(<issue>6</issue>):<fpage>705</fpage>&#8208;<lpage>714</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0277-9536(91)90150-b</pub-id><pub-id pub-id-type="pmid">2035047</pub-id></mixed-citation></ref><ref id="cam45755-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam45755-cit-0027"><string-name name-style="western"><surname>Brady</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Cella</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>F</given-names></string-name>, et al. <article-title>Reliability and validity of the functional assessment of cancer therapy&#8208;breast quality&#8208;of&#8208;life instrument</article-title>. <source>J Clin Oncol</source>. <year>1997</year>;<volume>15</volume>(<issue>3</issue>):<fpage>974</fpage>&#8208;<lpage>986</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.1997.15.3.974</pub-id><pub-id pub-id-type="pmid">9060536</pub-id></mixed-citation></ref><ref id="cam45755-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam45755-cit-0028"><string-name name-style="western"><surname>Matthies</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Taran</surname><given-names>F&#8208;A</given-names></string-name>, <string-name name-style="western"><surname>Keilmann</surname><given-names>L</given-names></string-name>, et al. <article-title>An electronic patient&#8208;reported outcome tool for the FACT&#8208;B (functional assessment of cancer therapy&#8208;breast) questionnaire for measuring the health&#8208;related quality of life in patients with breast cancer: reliability study</article-title>. <source>J Med Internet rResJournal of medical Internet research</source>. <year>2019</year>;<volume>21</volume>(<issue>1</issue>):<fpage>e10004</fpage>&#8208;<lpage>e</lpage>. doi:<pub-id pub-id-type="doi">10.2196/10004</pub-id><pub-id pub-id-type="pmcid">PMC6362389</pub-id><pub-id pub-id-type="pmid">30668517</pub-id></mixed-citation></ref><ref id="cam45755-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam45755-cit-0029"><string-name name-style="western"><surname>Hahn</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Segawa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kaiser</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cella</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>BD</given-names></string-name>. <article-title>Validation of the functional assessment of cancer therapy&#8208;breast (FACT&#8208;B) quality of life instrument</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>15_suppl</issue>):<fpage>e17753</fpage>&#8208;<lpage>e</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2015.33.15_suppl.e17753</pub-id></mixed-citation></ref><ref id="cam45755-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam45755-cit-0030"><string-name name-style="western"><surname>Fallowfield</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Leaity</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Benson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cella</surname><given-names>D</given-names></string-name>. <article-title>Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT&#8208;B</article-title>. <source>Breast Cancer res Treat</source>. <year>1999</year>;<volume>55</volume>(<issue>2</issue>):<fpage>187</fpage>&#8208;<lpage>197</lpage>. doi:<pub-id pub-id-type="doi">10.1023/A:1006263818115</pub-id><pub-id pub-id-type="pmid">10481946</pub-id></mixed-citation></ref><ref id="cam45755-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam45755-cit-0031"><string-name name-style="western"><surname>Cutillo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>O'Hea</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Person</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lessard</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Harralson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Boudreaux</surname><given-names>E</given-names></string-name>. <article-title>The distress thermometer: cutoff points and clinical use</article-title>. <source>Oncol Nurs Forum</source>. <year>2017</year>;<volume>44</volume>(<issue>3</issue>):<fpage>329</fpage>&#8208;<lpage>336</lpage>. doi:<pub-id pub-id-type="doi">10.1188/17.Onf.329-336</pub-id><pub-id pub-id-type="pmid">29493167</pub-id><pub-id pub-id-type="pmcid">PMC5839660</pub-id></mixed-citation></ref><ref id="cam45755-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam45755-cit-0032"><string-name name-style="western"><surname>Rovner</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Casten</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>LF</given-names></string-name>. <article-title>Cultural diversity and views on Alzheimer disease in older African Americans</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2013</year>;<volume>27</volume>(<issue>2</issue>):<fpage>133</fpage>&#8208;<lpage>137</lpage>. doi:<pub-id pub-id-type="doi">10.1097/WAD.0b013e3182654794</pub-id><pub-id pub-id-type="pmid">22828323</pub-id><pub-id pub-id-type="pmcid">PMC3492535</pub-id></mixed-citation></ref><ref id="cam45755-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam45755-cit-0033"><string-name name-style="western"><surname>LaVeist</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Isaac</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>KP</given-names></string-name>. <article-title>Mistrust of health care organizations is associated with underutilization of health services</article-title>. <source>Health Serv res</source>. <year>2009</year>;<volume>44</volume>(<issue>6</issue>):<fpage>2093</fpage>&#8208;<lpage>2105</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1475-6773.2009.01017.x</pub-id><pub-id pub-id-type="pmid">19732170</pub-id><pub-id pub-id-type="pmcid">PMC2796316</pub-id></mixed-citation></ref><ref id="cam45755-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam45755-cit-0034"><string-name name-style="western"><surname>Bird</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Bogart</surname><given-names>LM</given-names></string-name>. <article-title>Perceived race&#8208;based and socioeconomic status(SES)&#8208;based discrimination in interactions with health care providers</article-title>. <source>Ethn Dis</source>. <year>2001</year>;<volume>11</volume>(<issue>3</issue>):<fpage>554</fpage>&#8208;<lpage>563</lpage>.<pub-id pub-id-type="pmid">11572421</pub-id></mixed-citation></ref><ref id="cam45755-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam45755-cit-0035"><string-name name-style="western"><surname>Sutton</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Salgado</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hurtado&#8208;de&#8208;Mendoza</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>VB</given-names></string-name>. <article-title>Sociodemographic, clinical, psychosocial, and healthcare&#8208;related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors</article-title>. <source>Support Care Cancer</source>. <year>2020</year>;<volume>28</volume>(<issue>9</issue>):<fpage>4147</fpage>&#8208;<lpage>4154</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00520-019-05247-5</pub-id><pub-id pub-id-type="pmid">31897782</pub-id><pub-id pub-id-type="pmcid">PMC7329595</pub-id></mixed-citation></ref><ref id="cam45755-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="cam45755-cit-0036"><string-name name-style="western"><surname>Allison</surname><given-names>PD</given-names></string-name>. <article-title>Convergence Failures in Logistic Regression</article-title>. <year>2008</year>.</mixed-citation></ref><ref id="cam45755-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam45755-cit-0037"><string-name name-style="western"><surname>Carmona&#8208;Bayonas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jim&#233;nez&#8208;Fonseca</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Casta&#241;&#243;n</surname><given-names>E</given-names></string-name>, et al. <article-title>Chronic opioid therapy in long&#8208;term cancer survivors</article-title>. <source>Clin Transl Oncol</source>. <year>2017</year>;<volume>19</volume>(<issue>2</issue>):<fpage>236</fpage>&#8208;<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12094-016-1529-6</pub-id><pub-id pub-id-type="pmid">27443415</pub-id></mixed-citation></ref><ref id="cam45755-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cam45755-cit-0038"><string-name name-style="western"><surname>Correa</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Farney</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>J</given-names></string-name>. <article-title>Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations</article-title>. <source>Anesth Analg</source>. <year>2015</year>;<volume>120</volume>(<issue>6</issue>):<fpage>1273</fpage>&#8208;<lpage>1285</lpage>. doi:<pub-id pub-id-type="doi">10.1213/ane.0000000000000672</pub-id><pub-id pub-id-type="pmid">25988636</pub-id></mixed-citation></ref><ref id="cam45755-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cam45755-cit-0039"><string-name name-style="western"><surname>Lee</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Silverman</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>VB</given-names></string-name>, <string-name name-style="western"><surname>Manchikanti</surname><given-names>L</given-names></string-name>. <article-title>A comprehensive review of opioid&#8208;induced hyperalgesia</article-title>. <source>Pain Physician</source>. <year>2011</year>;<volume>14</volume>(<issue>2</issue>):<fpage>145</fpage>&#8208;<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.36076/ppj.2011/14/145</pub-id><pub-id pub-id-type="pmid">21412369</pub-id></mixed-citation></ref><ref id="cam45755-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cam45755-cit-0040"><string-name name-style="western"><surname>Vitzthum</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Nalawade</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Riviere</surname><given-names>P</given-names></string-name>, et al. <article-title>Racial, ethnic, and socioeconomic discrepancies in opioid prescriptions among older patients with cancer</article-title>. <source>JCO Oncol Prac</source>. <year>2021</year>;<volume>17</volume>(<issue>6</issue>):<fpage>e703</fpage>&#8208;<lpage>e713</lpage>. doi:<pub-id pub-id-type="doi">10.1200/OP.20.00773</pub-id><pub-id pub-id-type="pmcid">PMC8258011</pub-id><pub-id pub-id-type="pmid">33534647</pub-id></mixed-citation></ref><ref id="cam45755-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cam45755-cit-0041"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chittams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McMenamin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Fudin</surname><given-names>J</given-names></string-name>. <article-title>African Americans with cancer pain are more likely to receive an analgesic with toxic metabolite despite clinical risks: a mediation analysis study</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>25</issue>):<fpage>2773</fpage>&#8208;<lpage>2779</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.54.7992</pub-id><pub-id pub-id-type="pmid">25049323</pub-id><pub-id pub-id-type="pmcid">PMC4145186</pub-id></mixed-citation></ref><ref id="cam45755-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cam45755-cit-0042"><string-name name-style="western"><surname>Morin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zanville</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Guest</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rubens</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Currier</surname><given-names>MB</given-names></string-name>. <article-title>Prevalence and risk factors for vasomotor symptoms in Hispanic female breast cancer survivors, 0&#8211;3&#8201;years post&#8208;treatment: results of a single&#8208;center retrospective analysis</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>15_suppl</issue>):<fpage>e24038</fpage>&#8208;<lpage>e</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.e24038</pub-id></mixed-citation></ref><ref id="cam45755-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cam45755-cit-0043"><string-name name-style="western"><surname>O'Keefe</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Meltzer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Bethea</surname><given-names>TN</given-names></string-name>. <article-title>Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000&#8211;2010</article-title>. <source>Front Public Health</source>. <year>2015</year>;<volume>3</volume>:<elocation-id>51</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fpubh.2015.00051</pub-id><pub-id pub-id-type="pmid">25932459</pub-id><pub-id pub-id-type="pmcid">PMC4398881</pub-id></mixed-citation></ref><ref id="cam45755-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cam45755-cit-0044"><string-name name-style="western"><surname>DeSantis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bryan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jemal</surname><given-names>A</given-names></string-name>. <article-title>Breast cancer statistics, 2013</article-title>. <source>CA Cancer J Clin</source>. <year>2014</year>;<volume>64</volume>(<issue>1</issue>):<fpage>52</fpage>&#8208;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21203</pub-id><pub-id pub-id-type="pmid">24114568</pub-id></mixed-citation></ref><ref id="cam45755-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cam45755-cit-0045"><string-name name-style="western"><surname>Desai</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Camacho</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>LeBaron</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Blackhall</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Balkrishnan</surname><given-names>R</given-names></string-name>. <article-title>Mental health comorbidities and elevated risk of opioid use in elderly breast cancer survivors using adjuvant endocrine treatments</article-title>. <source>J Oncol Pract</source>. <year>2019</year>;<volume>15</volume>(<issue>9</issue>):<fpage>e777</fpage>&#8208;<lpage>e786</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JOP.18.00781</pub-id><pub-id pub-id-type="pmid">31322988</pub-id></mixed-citation></ref><ref id="cam45755-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cam45755-cit-0046"><string-name name-style="western"><surname>Tan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Camacho</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>LeBaron</surname><given-names>VT</given-names></string-name>, <string-name name-style="western"><surname>Blackhall</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Balkrishnan</surname><given-names>R</given-names></string-name>. <article-title>Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens</article-title>. <source>Breast Cancer res Treat</source>. <year>2017</year>;<volume>165</volume>(<issue>2</issue>):<fpage>455</fpage>&#8208;<lpage>465</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-017-4348-8</pub-id><pub-id pub-id-type="pmid">28639031</pub-id></mixed-citation></ref><ref id="cam45755-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cam45755-cit-0047"><string-name name-style="western"><surname>Seber</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Solmaz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yetisyigit</surname><given-names>T</given-names></string-name>. <article-title>Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting</article-title>. <source>Onco Targets Ther</source>. <year>2016</year>;<volume>9</volume>:<fpage>4929</fpage>&#8208;<lpage>4935</lpage>. doi:<pub-id pub-id-type="doi">10.2147/OTT.S108968</pub-id><pub-id pub-id-type="pmid">27563249</pub-id><pub-id pub-id-type="pmcid">PMC4984830</pub-id></mixed-citation></ref><ref id="cam45755-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="cam45755-cit-0048"><string-name name-style="western"><surname>Petrocchi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Filipponi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Montagna</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bonollo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pagani</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Meani</surname><given-names>F</given-names></string-name>. <article-title>A breast cancer smartphone app to navigate the breast cancer journey: mixed methods study</article-title>. <source>JMIR Form Res</source>. <year>2021</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e28668</fpage>. doi:<pub-id pub-id-type="doi">10.2196/28668</pub-id><pub-id pub-id-type="pmid">33970120</pub-id><pub-id pub-id-type="pmcid">PMC8145088</pub-id></mixed-citation></ref><ref id="cam45755-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cam45755-cit-0049"><string-name name-style="western"><surname>Alavi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Stephenson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>S</given-names></string-name>, et al. <article-title>Developing and implementing a web&#8208;based psychotherapy program to address mental health challenges among patients receiving oncologic and palliative care: protocol for an open&#8208;label randomized controlled trial</article-title>. <source>JMIR RES Protoc</source>. <year>2021</year>;<volume>10</volume>(<issue>7</issue>):<fpage>6</fpage>. doi:<pub-id pub-id-type="doi">10.2196/30735</pub-id><pub-id pub-id-type="pmcid">PMC8319771</pub-id><pub-id pub-id-type="pmid">34259164</pub-id></mixed-citation></ref><ref id="cam45755-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cam45755-cit-0050"><string-name name-style="western"><surname>Markman</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>McMahon</surname><given-names>CE</given-names></string-name>. <article-title>Integrated behavioral medicine in cancer care: utilizing a training program model to provide psychological services in an Urban Cancer Center</article-title>. <source>Curr Oncol Rep</source>. <year>2018</year>;<volume>20</volume>(<issue>4</issue>):<fpage>31</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s11912-018-0677-y</pub-id><pub-id pub-id-type="pmid">29572576</pub-id></mixed-citation></ref><ref id="cam45755-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cam45755-cit-0051"><string-name name-style="western"><surname>Au&#8208;Yeung</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Blewett</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Lange</surname><given-names>K</given-names></string-name>. <article-title>Addressing the rural opioid addiction and overdose crisis through cross&#8208;sector collaboration: little falls</article-title>. <source>Minnesota Am J Pub Health</source>. <year>2019</year>;<volume>109</volume>(<issue>2</issue>):<fpage>260</fpage>&#8208;<lpage>262</lpage>. doi:<pub-id pub-id-type="doi">10.2105/ajph.2018.304789</pub-id><pub-id pub-id-type="pmid">30571298</pub-id><pub-id pub-id-type="pmcid">PMC6336040</pub-id></mixed-citation></ref><ref id="cam45755-bib-0052"><label>52</label><mixed-citation publication-type="book" id="cam45755-cit-0052"><string-name name-style="western"><surname>Hedegaard</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mini&#241;o</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>M</given-names></string-name>. <part-title>Urban&#8211;rural differences in drug overdose death rates, by sex, age, and type of drugs involved</part-title>. <source>Statistics</source>. <publisher-name>NCfH</publisher-name>; <year>2019</year>.<pub-id pub-id-type="pmid">31442197</pub-id></mixed-citation></ref><ref id="cam45755-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="cam45755-cit-0053"><string-name name-style="western"><surname>Keyes</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Cerd&#225;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brady</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Havens</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Galea</surname><given-names>S</given-names></string-name>. <article-title>Understanding the rural&#8208;urban differences in nonmedical prescription opioid use and abuse in the United States</article-title>. <source>Am J Public Health</source>. <year>2014</year>;<volume>104</volume>(<issue>2</issue>):<fpage>e52</fpage>&#8208;<lpage>e59</lpage>. doi:<pub-id pub-id-type="doi">10.2105/AJPH.2013.301709</pub-id><pub-id pub-id-type="pmid">24328642</pub-id><pub-id pub-id-type="pmcid">PMC3935688</pub-id></mixed-citation></ref><ref id="cam45755-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="cam45755-cit-0054"><string-name name-style="western"><surname>Vanderpool</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, et al. <article-title>J Rural Health</article-title>. <source>The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association</source>. <year>2019</year>;<volume>35</volume>(<issue>2</issue>):<fpage>176</fpage>&#8208;<lpage>188</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jrh.12359</pub-id><pub-id pub-id-type="pmid">30830984</pub-id><pub-id pub-id-type="pmcid">PMC7219572</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>